Alpha-synucleinopathy and neuropsychological symptoms in a population-based cohort of the elderly

Alzheimer's Research and Therapy

Volumn 7, Issue 1, 2015, Pages

  Zaccai, Julia ^a   Brayne, Carol ^a   Matthews, Fiona E ^a   Ince, Paul G ^b  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN;

AGED; AGING; ALPHA SYNUCLEINOPATHY; AMYGDALOID NUCLEUS; ARTICLE; AUDITORY HALLUCINATION; COGNITION; COGNITIVE DEFECT; COHORT ANALYSIS; DEATH; DEMENTIA; DIFFUSE LEWY BODY DISEASE; DISEASE ASSOCIATION; DISEASE SEVERITY; GERIATRIC PATIENT; HALLUCINATION; HUMAN; HUMAN EXPERIMENT; HUMAN TISSUE; HYPOTHESIS; IMMUNOCYTOCHEMISTRY; NEUROLOGIC DISEASE; NEUROPSYCHOLOGY; ORGAN DONOR; PARKINSON DISEASE; PHENOTYPE; POPULATION RESEARCH; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT; SUBCORTEX; SUBSTANTIA NIGRA; VISUAL HALLUCINATION;

EID: 84927559202     PISSN: None     EISSN: 17589193     Source Type: Journal    
DOI: 10.1186/s13195-015-0101-x     Document Type: Article

References (40)

1. Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology. 1991;41:479-86.
2. Braak H, Braak E. Staging of Alzheimer's disease-related neurofibrillary changes. Neurobiol Aging. 1995;16:271-8.
3. Braak H, Del Tredici K, Rub U, de Vos RAI, Jansen Steur ENH, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging. 2003;24:197-211.
4. Neuropathology Group of the Medical Research Council Cognitive Function and Ageing Study. Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales. Lancet. 2001;357:169-75.
5. Wakisaka Y, Furuta A, Tanizaki Y, Kiyohara Y, Iida M, Iwaki T. Age-associated prevalence and risk factors of Lewy body pathology in a general population: the Hisayama study. Acta Neuropathol. 2003;106:374-82.
6. Parkkinen L, Pirttilä T, Alafuzoff I. Applicability of current staging/categorization of alpha-synuclein pathology and their clinical relevance. Acta Neuropathol. 2008;115:399-407.
7. Jellinger KA. Lewy body-related alpha-synucleinopathy in the aged human brain. J Neural Transm. 2004;111:1219-35.
8. Horvath J, Herrmann FR, Burkhard PR, Bouras C, Kövari E. Neuropathology of dementia in a large cohort of patients with Parkinson's disease. Parkinsonism Relat Disord. 2013;19:864-8.
9. Haroutunian V, Serby M, Purohit DP, Perl DP, Marin D, Lantz M, et al. Contribution of Lewy body inclusions to dementia in patients with and without Alzheimer disease neuropathological conditions. Arch Neurol. 2000;57:1145-50.
10. Hurtig HI, Trojanowski JQ, Galvin J, Ewbank D, Schmidt ML, Lee VM, et al. Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson's disease. Neurology. 2000;54:1916-21.
11. Mattila PM, Rinne JO, Helenius H, Dickson DW, Roytta M. Alpha-synuclein-immunoreactive cortical Lewy bodies are associated with cognitive impairment in Parkinson's disease. Acta Neuropathol. 2000;100:285-90.
12. Olichney JM, Galasko D, Salmon DP, Hofstetter CR, Hansen LA, Katzman R, et al. Cognitive decline is faster in Lewy body variant than in Alzheimer's disease. Neurology. 1998;51:351-7.
13. Wang DS, Bennett DA, Mufson E, Cochran E, Dickson DW. Decreases in soluble alpha-synuclein in frontal cortex correlate with cognitive decline in the elderly. Neurosci Lett. 2004;359:104-8.
14. Parkkinen L, Soininen H, Alafuzoff I. Regional distribution of alpha-synuclein pathology in unimpaired aging and Alzheimer disease. J Neuropathol Exp Neurol. 2003;62:363-7.
15. Sonnen J, Larson EB, Crane PK, Haneuse S, Li G, Schellenberg GD, et al. Pathological correlates of dementia in a longitudinal, population-based sample of aging. Ann Neurol. 2007;62:406-13.
16. Jellinger KA. Age-associated prevalence and risk factors of Lewy body pathology in a general population. Acta Neuropathol. 2003;106:383-4.
17. Xuereb JH, Brayne C, Dufouil C, Gertz H, Wischik C, Harrington C, et al. Neuropathological findings in the very old. Results from the first 101 brains of a population-based longitudinal study of dementing disorders. Ann NY Acad Sci. 2000;903:490-6.
18. White L, Petrovitch H, Hardman J, Nelson J, Davis DG. Cerebrovascular pathology and dementia in autopsied Honolulu-Asia Aging Study participants. Ann NY Acad Sci. 2002;977:9-23.
19. McKeith I, Mintzer J, Aarsland D, Burn D, Chiu H, Cohen-Mansfield J, et al. Dementia with Lewy bodies. Lancet Neurol. 2004;3:19-28.
20. Zaccai J, Ince P, Brayne C. Population-based neuropathological studies of dementia: design, methods and areas of investigation - a systematic review. BMC Neurol. 2006;6:2.
21. Cognitive function and dementia in six areas of England and Wales: the distribution of MMSE and prevalence of GMS organicity level in the MRC CFA Study. The Medical Research Council Cognitive Function and Ageing Study (MRC CFAS). Psychol Med. 1998;28:319-35.
22. Folstein MF, Folstein SE, McHugh PR. «Mini-mental state». A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189-98.
23. Copeland JR, Dewey ME, Griffiths-Jones HM. A computerized psychiatric diagnostic system and case nomenclature for elderly subjects: GMS and AGECAT. Psychol Med. 1986;16:89-99.
24. Roth M, Tym E, Mountjoy CQ, Hendrie H, Verma S, Goddard R. CAMDEX. A standardised instrument for the diagnosis of mental disorder in the elderly with special reference to the early detection of dementia. Br J Psychiatry. 1986;149:698-709.
25. Braak H, Braak E, Yilmazer D, de Vos RA, Jansen EN, Bohl J, et al. Amygdala pathology in Parkinson's disease. Acta Neuropathol. 1994;88:493-500.
26. Braak H, Braak E. Pathoanatomy of Parkinson's disease. J Neurol. 2000;247:II3-II10.
27. Del Tredici K, Rub U, De Vos RA, Bohl JR, Braak H. Where does parkinson disease pathology begin in the brain? J Neuropathol Exp Neurol. 2002;61:413-26.
28. Parkkinen L, Kauppinen T, Pirttila T, Autere JM, Alafuzoff I. Alpha-synuclein pathology does not predict extrapyramidal symptoms or dementia. Ann Neurol. 2005;57:82-91.
29. Saito Y, Kawashima A, Ruberu NN, Nyoka N, Fujiwara H, Koyama S, et al. Accumulation of phosphorylated alpha-synuclein in aging human brain. J Neuropathol Exp Neurol. 2003;62:644-54.
30. McKeith IG, Galasko D, Kosaka K, Perry EK, Dickson DW, Hansen LA, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology. 1996;47:1113-24.
31. Zaccai J, Brayne C, McKeith I, Matthews F, Ince PG. Patterns and stages of alpha-synucleinopathy: Relevance in a population-based cohort. Neurology. 2008;70:1042-8.
32. Kosaka K, Iseki E, Odawara T, Yamamoto T. Cerebral type of Lewy body disease. Neuropathology. 1996;16:2-35.
33. Hamilton RL. Lewy bodies in Alzheimer's disease: a neuropathological review of 145 cases using alpha-synuclein immunohistochemistry. Brain Pathol. 2000;10:378-84.
34. Uchikado H, Lin WL, DeLucia MW, Dickson DW. Alzheimer disease with amygdala Lewy bodies: a distinct form of alpha-synucleinopathy. J Neuropathol Exp Neurol. 2006;65:685-97.
35. Marui W, Iseki E, Nakai T, Miura S, Kato M, Ueda K, et al. Progression and staging of Lewy pathology in brains from patients with dementia with Lewy bodies. J Neurol Sci. 2002;195:153-9.
36. Popescu A, Lippa CF, Lee VM, Trojanowski JQ. Lewy bodies in the amygdala: increase of alpha-synuclein aggregates in neurodegenerative diseases with tau-based inclusions. Arch Neurol. 2004;61:1915-9.
37. Kosaka K. Diffuse Lewy body disease. Rinsho Shinkeigaku. 1995;35:1455-6.
38. Jellinger KA. A critical evaluation of current staging of alpha-synuclein pathology in Lewy body disorders. Biochim Biophys Acta. 2009;1792:730-40.
39. Foltynie T, Matthews FE, Ishihara L, Brayne C, MRC CFAS. The frequency and validity of self-reported diagnosis of Parkinson's Disease in the UK elderly: MRC CFAS cohort. BMC Neurol. 2006;6:29.
40. Beach TG, White 3rd CL, Hladik CL, Sabbagh MN, Connor DJ, Shill HA, et al. Olfactory bulb alpha-synucleinopathy has high specificity and sensitivity for Lewy body disorders. Acta Neuropathol. 2009;117:169-74.